secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIORA THERAPEUTICS, INC. (—)
CIK:        0001580063
Form:       8-K
Filed at:   2023-04-07T23:59:59+00:00
Accession:  0001193125-23-095373
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Biora Therapeutics receives Nasdaq delisting notice for failing $50M assets/revenue requirement
--------------------------------------------------------------------------------

- Notice on April 4, 2023: Nasdaq Staff says BIOR no longer meets $50M total assets and $50M total revenue requirement.
- No immediate delisting; company has 45 days (by May 19, 2023) to submit plan to regain compliance.
- If plan accepted, Staff may grant up to 180 days (through Oct 2, 2023) to evidence compliance.
- If plan not accepted, Staff issues delisting determination; appeal to Hearings Panel stays delisting.
- Company evaluating options but no assurance of extension or regaining compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1580063/000119312523095373/0001193125-23-095373-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1580063/000119312523095373/d489128d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-095373

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer